1-4 of 4
H Gabra
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract NTOC-116: THE TUMOUR SUPPRESSOR PROTEIN OPCML ACTS AS A SENSITIZING AGENT IN ANTI–EGFR/HER2 THERAPY AND CISPLATIN TREATMENT IN OVARIAN CANCER

E Zanini, LS Louis, J Antony, I Okon, AB McKie, C Recchi, H Gabra
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (11_Supplement): NTOC-116.
DOI: https://doi.org/10.1158/1557-3265.OVCASYMP16-NTOC-116
Published: 31 May 2017
View article
Journal Articles

Abstract AS20: DNA-PKcs is amplified in high grade serous ovarian cancer (HGSC), correlates with poor outcome and drives resistance to platinum therapy via the AKT signaling pathway

E Curry, A Cheraghchi-Bashi-Astaneh, M Chen, P Cunnea, C De Sousa, E Maginn, Y Dai, E Liu, H Wasan, G Mills, D Bowtell, H Gabra, EA Stronach
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (16_Supplement): AS20.
DOI: https://doi.org/10.1158/1557-3265.OVCASYMP14-AS20
Published: 15 August 2015
View article
Journal Articles

Functionality of the progesterone receptor in ovarian cancer and its regulation by estrogen.

S P Langdon, H Gabra, J M Bartlett, G J Rabiaz, R A Hawkins, A L Tesdale, A A Ritchie, W R Miller, J F Smyth
Journal: Clinical Cancer Research
Clin Cancer Res (1998) 4 (9): 2245–2251.
Published: 01 September 1998
View article
PDF
Journal Articles

Loss of heterozygosity at 11q22 correlates with low progesterone receptor content in epithelial ovarian cancer.

H Gabra, S P Langdon, J E Watson, R A Hawkins, B B Cohen, L Taylor, J Mackay, C M Steel, R C Leonard, J F Smyth
Journal: Clinical Cancer Research
Clin Cancer Res (1995) 1 (9): 945–953.
Published: 01 September 1995
View article
PDF